- Cardlytics, Inc (NASDAQ:CDLX) shares are up over 30% on Tuesday morning following its raised guidance for the first quarter that ended March 31, 2023.
- The company increased its first-quarter revenue outlook to $63.5 million – $66.5 million, up from $54.0 million – $63.0 million (consensus $57.94 million).
- Cardlytics raised its Q1 billings to $93.0 million – $97.0 million, up from the previous $84.0 million – $93.0 million.
- The company now expects a Q1 adjusted EBITDA loss of $(8.0) million – $(5.0) million versus the prior $(17.0) million – $(10.0) million.
- “Despite a difficult macroeconomic environment, our shift to a product-led operating structure is already yielding positive results,” said Cardlytics CEO Karim Temsamani. “Our improved topline guidance is driven by better-than-expected growth in the US business and the product optimizations discussed on our last earnings call. Additionally, our rigorous approach in managing our cost structure, including implementing $3.5 million of one-time savings during the first quarter, has positioned the business to exceed the high end of our previously announced Adjusted EBITDA range.”
- Price Action: CDLX shares traded higher by 30.43% at $4.50 on the last check Tuesday.
GoodRx Expands Executive Team With Scott Wagner, Former CEO Of GoDaddy, Appointed Interim CEO; Co-Founders Doug Hirsch and Trevor Bezdek To Serve As Chief MissionOfficer and Chairman, Respectively
Scott Wagner, Former CEO of GoDaddy, Appointed Interim CEO
GoodRx Co-Founders Doug Hirsch and Trevor Bezdek to Serve as Chief MissionOfficer and Chairman, Respectively
GoodRx Holdings, Inc. (NASDAQ:GDRX), a
